Horizon2020 articles on TBVAC2020

21st march 2016, an article was published about the first TBVAC2020 project meeting (Les Diablerets, Switzerland), which provided the first results of R&D activities, including vaccine discovery and biomarkers of immunity and protection.

April 2015, an article was published about the launch of the TBVAC2020 project in Issue 6 of the Horizon2020 Projects Portal (page 190)

January 2015, an article was published about TBVI being awarded a €24m EC grant to progress the TBVAC2020 project.

Opinion article in The Hindu

On the 21st of February, 2016, the following opinion article was published in The Hindu: Revamped, safer, and with greater punch.

All eyes are on a new BCG-based TB vaccine, VPM1002, which has shown promise in animal and small-scale human trials. It is to be supplied by the Pune-based Serum Institute of India.

The article includes quotes from Professor dr dr h.c. Stefan Kaufmann of the TBVAC2020 partner Max Planck Institute for Infection Biology.

Annual meeting TBVAC2020

The first annual meeting of the TBVAC2020 project was held from 1-5 Frebruary 2016 in Les Diablerets, Switzerland. This meeting was for TBVAC2020 project members only. The programme also included the symposium ‘TB Vaccines and Immunity’, open for everyone.

The programme of the (closed) annual meeting can be viewed here.
Read the summary of the meeting.

February 1, 2016: Tuberculosis: discovery of a critical stage in the evolution of the bacillus towards pathogenicity

Read the press release of our partners Institut Pasteur and CNRS.

January 14, 2016: Zaragoza scientist from TBVI network awarded

Read the message about Nacho Aguilo from our partner University of Zaragoza.

Calls for applications of preclinical models – TBVAC2020
Please note: this call is for TBVAC2020 project members only

Progression of TB vaccines through the discovery, pre-clinical and clinical stages of development requires demonstration of safety, immunogenicity and the ability to reduce or prevent TB disease. This is achieved by testing vaccine candidates in preclinical models. TBVAC2020 uses standardised, head-to-head models for the screening of promising vaccine candidates in independent laboratories. The evaluation in these head-to-head models will support the pre-clinical development activities of the project and will assist in decision making in portfolio management using predefined, objective gating and priority setting criteria (WP6). These standardised models and established/accepted read-outs will provide evidence of safety, immunogenicity and/or protective efficacy of new vaccine candidates.
During the course of the TBVAC2020 project, several calls for applications will be sent out to the partners of the project. The project partners will be invited to submit their proposals for evaluating their vaccine candidates in the following models:

Model A: Adjuvanted vaccines head to head comparison
Model B: Mouse model for protective efficacy against clinical (Beijing) strains of M.tb.
Model C: Guinea pig model for protective efficacy.
Model D: Mouse model for efficacy testing of post-exposure vaccination.
Model E: SCID mouse model for safety of live vaccines.
Model F: Standard immune competent mouse model for protective efficacy
Model G: GMP, adjuvant and formulation studies
Model H: Comparative phase 1 clinical trial

The first call was sent out in March 2015, the second on 10 September 2015. Upcoming calls are expected in March and September 2016 and a final call in March 2017.
TBVI’s portfolio management committee evaluates the applications and prioritises according to the criteria indicated in the call texts. For more information please contact Daniëlle Roordink TBVI project manager.